PTC Therapeutics reports positive Phase III trial results of ataluren in nmCF patients
US-based biopharmaceutical firm PTC Therapeutics has reported results of a Phase III double-blind, placebo-controlled trial of ataluren in patients with nonsense mutation cystic fibrosis (nmCF).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cystic Fibrosis | Pharmaceuticals